Earnings Feed
Start Free
Home/Filings/4/0001567619-22-018437
4//SEC Filing

Silva Francisco 4

Accession 0001567619-22-018437

CIK 0001505497other
View on SEC.govCompany Profile

Filed

Oct 11, 8:00 PM ET

Accepted

Oct 12, 2:01 PM ET

Size

19.4 KB

Accession

0001567619-22-018437

Insider Transaction Report

Form 4
Period: 2022-10-12
BioRestorative Therapies, Inc.BRTX
Silva Francisco
VP of Research and Development
Transactions
  • Purchase

    Common Stock

    2022-10-12$3.39/sh+725$2,457→ 165,103 total
Holdings

  • Common Stock

    (indirect: By IRA)
    12,136

  • Stock Option

    Exercise: $3000.00Exp: 2024-02-18→ Common Stock (3 underlying)
    3

  • Stock Option

    Exercise: $3000.00Exp: 2025-09-04→ Common Stock (6 underlying)
    6

  • Stock Option

    Exercise: $3000.00Exp: 2028-10-29→ Common Stock (25 underlying)
    25

  • Stock Option

    Exercise: $3000.00Exp: 2022-12-07→ Common Stock (1 underlying)
    1

  • Stock Option

    Exercise: $3000.00Exp: 2027-07-12→ Common Stock (20 underlying)
    20

  • Stock Option

    Exercise: $3000.00Exp: 2024-10-23→ Common Stock (9 underlying)
    9

  • Stock Option

    Exercise: $13.50Exp: 2031-03-18→ Common Stock (293,479 underlying)
    293,479

  • Stock Option

    Exercise: $3000.00Exp: 2023-10-04→ Common Stock (1 underlying)
    1

  • Stock Option

    Exercise: $3000.00From: 2014-03-12Exp: 2024-03-11→ Common Stock (1 underlying)
    1

  • Stock Option

    Exercise: $3000.00Exp: 2026-06-10→ Common Stock (15 underlying)
    15

  • Stock Option

    Exercise: $13.50Exp: 2031-11-04→ Common Stock (42,059 underlying)
    42,059
Footnotes (4)
  • [F1]Includes 104,045 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on each of October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on each of November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
  • [F2]The option is currently exercisable.
  • [F3]The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
  • [F4]The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.

Documents

1 file

Issuer

BioRestorative Therapies, Inc.

CIK 0001505497

→
Entity typeother

Related Parties

1
  • filerCIK 0001527241

Filing Metadata

Form type
4
Filed
Oct 11, 8:00 PM ET
Accepted
Oct 12, 2:01 PM ET
Size
19.4 KB
View on SEC.gov